TheraRadar
Data updated: Jun 28, 2026

PIVYA (pivmecillinam hydrochloride) · ALEMBIC THERAP

Infectious Disease Approved 2024-04-24

Pivya is a penicillin-class antibiotic that treats uncomplicated urinary tract infections in women 18 years of age and older. It helps patients with infections caused by specific bacteria such as *E. coli*, *Proteus mirabilis*, and *Staphylococcus saprophyticus*. This medication is used to manage these infections while helping to prevent the development of drug-resistant bacteria.

1
Indication
--
Phase 3 Trials
1
Priority Reviews
2
Years on Market

Details

Status
Prescription
First Approved
2024-04-24
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: PIVMECILLINAM HYDROCHLORIDE

PIVYA Approval History

2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2024 to 2024
Apr 2024 ORIGINAL Priority
New Ingredient · Type 2 - New Active Ingredient

What PIVYA Treats

1 indications

PIVYA is approved for 1 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.

Source: FDA Label

PIVYA Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to PIVYA

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AMIKACIN SULFATE
AMIKACIN SULFATE
1 shared
QILU
Shared indications:
AMOXICILLIN PEDIATRIC
AMOXICILLIN
1 shared
Teva
Shared indications:
AMPICILLIN SODIUM
AMPICILLIN SODIUM
1 shared
WATSON LABS INC
Shared indications:
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PIVYA FDA Label Details

Indications & Usage

FDA Label (PDF)

PIVYA is a penicillin class antibacterial indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus . To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIVYA and other antibacterial drugs, PIVYA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. 1.1 Uncomplicated Urinary Tract Infections PIVYA is indicated for the treatment of f...

Track PIVYA with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.